1
|
Brunelli M, Schwaar M, Isensee C, Goth S, Schmidt H, Heitmann A. Very (70W) vs. LSI guided (5-6) high power short duration ablation in patients with paroxysmal atrial fibrillation undergoing pulmonary vein vs. pulmonary vein and posterior wall isolation. Europace 2021. [DOI: 10.1093/europace/euab116.082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
high power short duration (HPSD) ablation is at least as safe while reducing procedure time than radiofrequency (RF) ablation with lower power in pts undergoing pulmonary vein isolation (PVI) for paroxysmal atrial fibrillation (AF). Purpose: to compare safety and efficacy of 2 different: 1) RF energy set up (FlexAbility: 70W, 41°, 6-10s, 11ml/h vs. TactiCath: 50W, 41°, LSI 5-6, 17ml/h, both Abbott), and 2) ablation strategies (posterior wall isolation (PWI) in addition to PVI vs. PVI) in pts undergoing their first ablation for paroxysmal AF. Methods: since June 2020 pts are prospectively assigned to alternatively undergo their RF catheter ablation with the FlexAbility (v-HPSD) or the TactiCath (LSI-HPSD) catheters (aim 200 pts). In addition, pts were alternatively assigned to PVI + PWI vs. PVI. All procedures were done using a 3D-mapping system (Ensite Precision), the ablation catheter was stabilized with a long sheath (Agilis) and a continuous series of lesions (4mm) were plotted around the PV, at the roof and between the 2 inferior PVs. On the PW, RF lesions were limited to 6s and 5 LSI for the v-HPSD and LSI-HPSD groups. Endoscopy was performed shortly after ablation in all pts and thermal esophageal lesion (TEL) characterized with the Kansas classification. Results: since June 2020 56 pts [61 ± 13 years old, 17 (30%) female, CHA2DS2-Vasc 2.3 ± 1.5, 55 ± 77 left ventricular ejection fraction] underwent v-HPSD (#28) and LSI-HPSD (#28) ablation. In 2/14 (14%) and in 3/15 (20%) pts (v-HPSD and LSI-HPSD groups, respectively) initially assigned to undergo simple PVI, PWI was added due to PW dependent flutter or evidence of pro-arrhythmic slow conduction on the PW. A shorter RF time to achieve PVI (17 ± 3 vs. 25 ± 6 min; P<.0001) was found for the v-HPSD group, although acute reconnection were numerically higher (9 vs. 4) and procedural time did not differ (32 ± 8 vs. 35 ± 9 min). Whenever attempted, PWI (#16 for each v-HPSD and LSI-HPSD group) was always successful. When v-HPSD and LSI-HPSD group were compared, no differences were found in RF and procedure time both at the roof (2.3 ± 0.9 vs. 2.7 ± 1.1 min and 3 ± 1.4 vs. 3.4 ± 1 min, respectively) and between the 2 inferior PVs (2.6 ± 0.6 vs. 2.9 ± 0.7 min and 4.3 ± 1.9 vs. 3.8 ± 1.2 min, respectively). Total RF (19.7 ± 4.5 vs. 28.5 ± 6.6 min, P<.0001) was shorted in the v-HPSD, but X-Ray (1.4 ± 0.7 vs. 1.2 ± 0.8 min) and total procedural time (102 ± 17 vs. 110 ± 20 min) did not differ. Rate of TELs was not different and found in 18% (#5: 4 I, 1 IIA) and 14% (all IIA) pts assigned to v-HPSD and LSI-HPSD respectively. A numerically higher number of TELs (6 vs. 3) was seen when PWI was pursued, although this did not prolong total RF and procedure time. Conclusion: a shorter RF time is associated with v-HPSD vs. LSI-HPSD strategy, although procedural time did not differ. TELs are a relative rare finding, and only numerically higher when isolation of the PW is pursued in addition to PV isolation.
Collapse
Affiliation(s)
- M Brunelli
- Hospital Magdeburg, Electrophysiology Section, Department of Cardiology and Diabetology, Magdeburg, Germany
| | - M Schwaar
- Hospital Magdeburg, Electrophysiology Section, Department of Cardiology and Diabetology, Magdeburg, Germany
| | - C Isensee
- Hospital Magdeburg, Electrophysiology Section, Department of Cardiology and Diabetology, Magdeburg, Germany
| | - S Goth
- Hospital Magdeburg, Electrophysiology Section, Department of Cardiology and Diabetology, Magdeburg, Germany
| | - H Schmidt
- Hospital Magdeburg, Division of Cardiology, Magdeburg, Germany
| | - A Heitmann
- Hospital Magdeburg, Electrophysiology Section, Department of Cardiology and Diabetology, Magdeburg, Germany
| |
Collapse
|
2
|
Brunelli M, Schwaar M, Isensee C, Opara W, Michael T, Heitmann A, Schmidt H. 1249Acute efficacy and safety of pulmonary vein isolation for atrial fibrillation in patients alternatively assigned to high power short duration (70W, 8s) vs lesion index guided (35W) ablation. Europace 2020. [DOI: 10.1093/europace/euaa162.360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
permanent trans-mural lesions not affecting surrounding anatomical structures is the goal of safe and effective wide antral pulmonary vein (PV) isolation in patients with paroxysmal and persistent atrial fibrillation (AF) undergoing catheter ablation (CA). Time, energy and contact force are parameters related to lesion goodness and incorporated in a complex formula (i.e. the lesion index, LSI™, Abbott). This parameter is emerging as the gold standard for PV isolation. Recently, the shallower but wider lesions created by high power short duration (HPSD) ablation has came to attention.
Purpose
to compare acute reconnection rate, procedural parameters, and complication rates in patients with paroxysmal or persistent AF undergoing CA.
Methods
one-hundred patients with paroxysmal and 100 with persistent AF will be alternatively assigned to undergo PV isolation with the FlexAbility™ (HPSD group, 70W, 41°, 8 seconds) or the TactiCath™ (LSI-group: 35W, 41°, LSI: 5-5.5 posterior wall, up to ≥6 anywhere else) catheter. A 3-D mapping system (Ensite Precision™) and a steerable sheath (Agilis™, both Abbott) were always used. Adenosine (30mg) is given after PV isolation and ≥ 20 minutes waiting time. Posterior wall isolation was added in all, and patients with persistent AF were additionally treated with mitral and cavotricuspid isthmus ablation. Results: between June and October 2019, 71 patients (68 ± 10 years old, 32 (45%) female, 44 (60%) paroxysmal AF, AF duration 58 ± 81 months) were alternatively assigned to HPSD (36, 51%) or LSI-guided (35, 49%) ablation. No difference in clinical characteristics was found between groups. After 44 ± 18 and 30 ± 14min of procedural and RF time, all PVs were isolated, and all 17 (24%) reconnections treated with an additional 4 ± 3 and 3 ± 2min, respectively. In 8 ± 3 and 7 ± 3 min of procedural and RF time, the PW was successfully isolated in all. PV isolation (34 ± 12min vs. 56 ± 16min; P<.0001), RF (18 ± 5min vs. 41 ± 9min; P<.0001), and total procedural (138 ± 34min vs. 162 ± 34min; P=.0026) time were shorter in the HPSD group. X-Ray time and effective dose did not differ. A similar rate of acute reconnections (9, 25% vs. 8 23%) was found when HPSD and LSI were compared. A higher, although statistically not significant, number of steam pops was observed in the HPSD (14, 39%) vs. LSI (8, 23%) group, possibly related to the higher incidence of moderate pericardial effusion (>0.5mm, <20mm) found the day following the ablation (10, 28% vs. 2, 6%; P=.0238). No further complications related to CA were detected.
Conclusions
in patients with paroxysmal and persistent AF undergoing their first CA, HPSD ablation is faster than an LSI-guided approach. Acute efficacy (reconnection rate) is similar. Although a higher rate of haemodynamically non-relevant pericardial effusions were seen in the HPSD group, these were all treated medically and the general safety profile of this approach is excellent and comparable to LSI ablation.
Collapse
Affiliation(s)
- M Brunelli
- Hospital Magdeburg, Electrophysiology Section, Department of Cardiology and Diabetology, Magdeburg, Germany
| | - M Schwaar
- Hospital Magdeburg, Electrophysiology Section, Department of Cardiology and Diabetology, Magdeburg, Germany
| | - C Isensee
- Hospital Magdeburg, Electrophysiology Section, Department of Cardiology and Diabetology, Magdeburg, Germany
| | - W Opara
- Hospital Magdeburg, Division of Cardiology, Magdeburg, Germany
| | | | | | - H Schmidt
- Hospital Magdeburg, Division of Cardiology, Magdeburg, Germany
| |
Collapse
|
3
|
Brunelli M, Opara W, Schwaar M, John N, Isensee C, Lutze G, Adler J, Heitmann A, Michael T, Gottstein T, Schmidt H. 1247Similar rate of thermal esophageal lesions are found in patients alternatively assigned to high power short duration (70W, 8s) vs. lesion index guided (35W) ablation for atrial fibrillation. Europace 2020. [DOI: 10.1093/europace/euaa162.361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background
wide antral pulmonary vein (PV) catheter ablation (CA) in patients with atrial fibrillation (AF) is safe and effective when permanent trans-mural lesions are achieved without causing harm to surrounding anatomical structures. Atrio-esophageal fistula, due to its high mortality, is the most dreadful complication related to CA for AF, therefore alternative radiofrequency (RF) approaches to reduce or eliminate this complication are currently studied. The shallower but wider lesions of high power short duration (HPSD) ablation might represent a safe alternative.
Purpose
to compare the rate of thermal esophageal lesions in patients with paroxysmal and persistent AF undergoing CA assigned to the 2 different RF modality.
Methods
one-hundred patients with paroxysmal and 100 with persistent AF will be alternatively assigned to undergo CA with the FlexAbility™ (HPSD group: 70W, 41°, 8 seconds) or the TactiCath™ (LSI-group: 35W, 41°, LSI: 5-5.5 posterior wall, up to 6 anywhere else) catheter. A 3-D mapping system, a steerable sheath and adenosine-test (30mg) were used in all patients. Posterior wall (PW) isolation in addition to PV isolation was performed in all, and patients with persistent AF were additionally treated with mitral and cavotricuspid isthmus ablation. Insertion of an esophageal probe was always attempted, and all patients underwent upper endoscopy 24 to 48 hours after CA.
Results
between June and October 2019, 71 patients (68 ± 10 years old, 32 (45%) female, 44 (60%) paroxysmal AF, AF duration 58 ± 81 months) were alternatively assigned to HPSD (36, 51%) or LSI-guided (35, 49%) ablation. No differences in clinical characteristics were found between groups. After 45 ± 18min and 30 ± 14 min of procedural and RF time, all PVs were isolated, and all spontaneous and adenosine-induced reconnections treated. Successful PW isolation was achieved with an additional 8 ± 3 and 7 ± 3 min of procedural and RF time. When HPSD and LSI-guided groups are compared, a similar rate of clinically non-relevant and self-healing thermal lesions at endoscopy was found (10, 27.8% vs. 10, 28.6%). Independent of the treatment group, a higher peak temperature identified patients with esophageal lesions (43.2° vs. 42°; P=.0065). A peak temperature value of 43.1° best identify patients most likely to develop thermal lesions (AUC 0.71, SE 84%, SP 39%). Interestingly, none of the 11 patients in whom esophageal probe insertion was not possible or attempted developed thermal lesions in comparison to 20 (33%) patients who underwent esophageal temperature monitoring (P=.0046). Conclusions: no difference in thermal induced esophageal lesions were found when the two different RF approach (HPSD vs. LSI guided) were compared. Interestingly, lack of temperature monitoring with an esophageal probe is associated with no thermal lesions at endoscopy.
Collapse
Affiliation(s)
- M Brunelli
- Hospital Magdeburg, Electrophysiology Section, Department of Cardiology and Diabetology, Magdeburg, Germany
| | - W Opara
- Hospital Magdeburg, Division of Cardiology, Magdeburg, Germany
| | - M Schwaar
- Hospital Magdeburg, Electrophysiology Section, Department of Cardiology and Diabetology, Magdeburg, Germany
| | - N John
- Clinic Magdeburg, Department of Gastroenterology, Magdeburg, Germany
| | - C Isensee
- Hospital Magdeburg, Electrophysiology Section, Department of Cardiology and Diabetology, Magdeburg, Germany
| | - G Lutze
- Clinic Magdeburg, Department of Gastroenterology, Magdeburg, Germany
| | - J Adler
- Clinic Magdeburg, Department of Gastroenterology, Magdeburg, Germany
| | | | | | - T Gottstein
- Clinic Magdeburg, Department of Gastroenterology, Magdeburg, Germany
| | - H Schmidt
- Hospital Magdeburg, Division of Cardiology, Magdeburg, Germany
| |
Collapse
|
5
|
Blutke A, Renner S, Flenkenthaler F, Backman M, Haesner S, Kemter E, Ländström E, Braun-Reichhart C, Albl B, Streckel E, Rathkolb B, Prehn C, Palladini A, Grzybek M, Krebs S, Bauersachs S, Bähr A, Brühschwein A, Deeg CA, De Monte E, Dmochewitz M, Eberle C, Emrich D, Fux R, Groth F, Gumbert S, Heitmann A, Hinrichs A, Keßler B, Kurome M, Leipig-Rudolph M, Matiasek K, Öztürk H, Otzdorff C, Reichenbach M, Reichenbach HD, Rieger A, Rieseberg B, Rosati M, Saucedo MN, Schleicher A, Schneider MR, Simmet K, Steinmetz J, Übel N, Zehetmaier P, Jung A, Adamski J, Coskun Ü, Hrabě de Angelis M, Simmet C, Ritzmann M, Meyer-Lindenberg A, Blum H, Arnold GJ, Fröhlich T, Wanke R, Wolf E. The Munich MIDY Pig Biobank - A unique resource for studying organ crosstalk in diabetes. Mol Metab 2017; 6:931-940. [PMID: 28752056 PMCID: PMC5518720 DOI: 10.1016/j.molmet.2017.06.004] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/05/2017] [Revised: 06/05/2017] [Accepted: 06/06/2017] [Indexed: 02/06/2023] Open
Abstract
OBJECTIVE The prevalence of diabetes mellitus and associated complications is steadily increasing. As a resource for studying systemic consequences of chronic insulin insufficiency and hyperglycemia, we established a comprehensive biobank of long-term diabetic INSC94Y transgenic pigs, a model of mutant INS gene-induced diabetes of youth (MIDY), and of wild-type (WT) littermates. METHODS Female MIDY pigs (n = 4) were maintained with suboptimal insulin treatment for 2 years, together with female WT littermates (n = 5). Plasma insulin, C-peptide and glucagon levels were regularly determined using specific immunoassays. In addition, clinical chemical, targeted metabolomics, and lipidomics analyses were performed. At age 2 years, all pigs were euthanized, necropsied, and a broad spectrum of tissues was taken by systematic uniform random sampling procedures. Total beta cell volume was determined by stereological methods. A pilot proteome analysis of pancreas, liver, and kidney cortex was performed by label free proteomics. RESULTS MIDY pigs had elevated fasting plasma glucose and fructosamine concentrations, C-peptide levels that decreased with age and were undetectable at 2 years, and an 82% reduced total beta cell volume compared to WT. Plasma glucagon and beta hydroxybutyrate levels of MIDY pigs were chronically elevated, reflecting hallmarks of poorly controlled diabetes in humans. In total, ∼1900 samples of different body fluids (blood, serum, plasma, urine, cerebrospinal fluid, and synovial fluid) as well as ∼17,000 samples from ∼50 different tissues and organs were preserved to facilitate a plethora of morphological and molecular analyses. Principal component analyses of plasma targeted metabolomics and lipidomics data and of proteome profiles from pancreas, liver, and kidney cortex clearly separated MIDY and WT samples. CONCLUSIONS The broad spectrum of well-defined biosamples in the Munich MIDY Pig Biobank that will be available to the scientific community provides a unique resource for systematic studies of organ crosstalk in diabetes in a multi-organ, multi-omics dimension.
Collapse
Key Words
- Biobank
- CE, cholesterol ester
- CPT1, carnitine O-palmitoyltransferase 1
- ER, endoplasmic reticulum
- FFA, free fatty acids
- Hyperglycemia
- Insulin insufficiency
- MIDY
- MIDY, mutant INS gene-induced diabetes of youth
- Metabolomics
- PC, phosphatidylcholine
- PCA, principal component analysis
- Pig model
- Proteomics
- Random systematic sampling
- SM, sphingomyelin
- Stereology
- TAG, triacylglycerol
- Transcriptomics
- WT, wild-type
Collapse
Affiliation(s)
- Andreas Blutke
- Institute of Veterinary Pathology at the Centre for Clinical Veterinary Medicine, LMU Munich, Veterinärstr. 13, D-80539 Munich, Germany
| | - Simone Renner
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, and Center for Innovative Medical Models (CiMM), LMU Munich, Feodor-Lynen-Str. 25, D-81377 Munich, Germany; German Center for Diabetes Research (DZD), Ingolstädter Landstr. 1, D-85764 Neuherberg, Germany
| | - Florian Flenkenthaler
- Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Feodor-Lynen-Str. 25, D-81377 Munich, Germany
| | - Mattias Backman
- Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Feodor-Lynen-Str. 25, D-81377 Munich, Germany
| | - Serena Haesner
- Institute of Veterinary Pathology at the Centre for Clinical Veterinary Medicine, LMU Munich, Veterinärstr. 13, D-80539 Munich, Germany
| | - Elisabeth Kemter
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, and Center for Innovative Medical Models (CiMM), LMU Munich, Feodor-Lynen-Str. 25, D-81377 Munich, Germany
| | - Erik Ländström
- Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Feodor-Lynen-Str. 25, D-81377 Munich, Germany
| | - Christina Braun-Reichhart
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, and Center for Innovative Medical Models (CiMM), LMU Munich, Feodor-Lynen-Str. 25, D-81377 Munich, Germany
| | - Barbara Albl
- Institute of Veterinary Pathology at the Centre for Clinical Veterinary Medicine, LMU Munich, Veterinärstr. 13, D-80539 Munich, Germany
| | - Elisabeth Streckel
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, and Center for Innovative Medical Models (CiMM), LMU Munich, Feodor-Lynen-Str. 25, D-81377 Munich, Germany
| | - Birgit Rathkolb
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, and Center for Innovative Medical Models (CiMM), LMU Munich, Feodor-Lynen-Str. 25, D-81377 Munich, Germany; German Center for Diabetes Research (DZD), Ingolstädter Landstr. 1, D-85764 Neuherberg, Germany; German Mouse Clinic (GMC), Institute of Experimental Genetics, Helmholtz Zentrum München, Ingolstädter Landstr. 1, D-85764 Neuherberg, Germany
| | - Cornelia Prehn
- Genome Analysis Center (GAC), Institute of Experimental Genetics, Helmholtz Zentrum München, Ingolstädter Landstr. 1, D-85764 Neuherberg, Germany
| | - Alessandra Palladini
- German Center for Diabetes Research (DZD), Ingolstädter Landstr. 1, D-85764 Neuherberg, Germany; Paul Langerhans Institute Dresden of the Helmholtz Zentrum München at the University Hospital and Faculty of Medicine Carl Gustav Carus of TU Dresden, Fetscherstr. 74, D-01307 Dresden, Germany
| | - Michal Grzybek
- German Center for Diabetes Research (DZD), Ingolstädter Landstr. 1, D-85764 Neuherberg, Germany; Paul Langerhans Institute Dresden of the Helmholtz Zentrum München at the University Hospital and Faculty of Medicine Carl Gustav Carus of TU Dresden, Fetscherstr. 74, D-01307 Dresden, Germany
| | - Stefan Krebs
- Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Feodor-Lynen-Str. 25, D-81377 Munich, Germany
| | - Stefan Bauersachs
- Animal Physiology, Institute of Agricultural Sciences, ETH Zurich, Universitätsstr. 2, CH-8092 Zurich, Switzerland
| | - Andrea Bähr
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, and Center for Innovative Medical Models (CiMM), LMU Munich, Feodor-Lynen-Str. 25, D-81377 Munich, Germany
| | - Andreas Brühschwein
- Clinic for Small Animal Surgery and Reproduction, Center for Clinical Veterinary Medicine, LMU Munich, Veterinärstr. 13, D-80539 Munich, Germany
| | - Cornelia A Deeg
- Experimental Ophthalmology, Philipps University of Marburg, Baldingerstr., D-35033 Marburg, Germany; Chair for Animal Physiology, Department of Veterinary Sciences, LMU Munich, Veterinärstr. 13, D-80539 Munich, Germany
| | - Erica De Monte
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, and Center for Innovative Medical Models (CiMM), LMU Munich, Feodor-Lynen-Str. 25, D-81377 Munich, Germany
| | - Michaela Dmochewitz
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, and Center for Innovative Medical Models (CiMM), LMU Munich, Feodor-Lynen-Str. 25, D-81377 Munich, Germany
| | - Caroline Eberle
- Institute of Veterinary Pathology at the Centre for Clinical Veterinary Medicine, LMU Munich, Veterinärstr. 13, D-80539 Munich, Germany
| | - Daniela Emrich
- Institute of Veterinary Pathology at the Centre for Clinical Veterinary Medicine, LMU Munich, Veterinärstr. 13, D-80539 Munich, Germany
| | - Robert Fux
- Institute for Infectious Diseases and Zoonosis, LMU Munich, Veterinärstr. 13, D-80539 Munich, Germany
| | - Frauke Groth
- Institute of Veterinary Pathology at the Centre for Clinical Veterinary Medicine, LMU Munich, Veterinärstr. 13, D-80539 Munich, Germany
| | - Sophie Gumbert
- Clinic for Swine at the Centre of Clinical Veterinary Medicine, LMU Munich, Sonnenstr. 16, D-85764 Oberschleißheim, Germany
| | - Antonia Heitmann
- Institute of Veterinary Pathology at the Centre for Clinical Veterinary Medicine, LMU Munich, Veterinärstr. 13, D-80539 Munich, Germany
| | - Arne Hinrichs
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, and Center for Innovative Medical Models (CiMM), LMU Munich, Feodor-Lynen-Str. 25, D-81377 Munich, Germany
| | - Barbara Keßler
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, and Center for Innovative Medical Models (CiMM), LMU Munich, Feodor-Lynen-Str. 25, D-81377 Munich, Germany
| | - Mayuko Kurome
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, and Center for Innovative Medical Models (CiMM), LMU Munich, Feodor-Lynen-Str. 25, D-81377 Munich, Germany
| | - Miriam Leipig-Rudolph
- Institute of Veterinary Pathology at the Centre for Clinical Veterinary Medicine, LMU Munich, Veterinärstr. 13, D-80539 Munich, Germany
| | - Kaspar Matiasek
- Institute of Veterinary Pathology at the Centre for Clinical Veterinary Medicine, LMU Munich, Veterinärstr. 13, D-80539 Munich, Germany; Munich Center of NeuroSciences - Brain & Mind, Großhaderner Str. 2, D-82152 Planegg-Martinsried, Germany
| | - Hazal Öztürk
- Institute of Veterinary Pathology at the Centre for Clinical Veterinary Medicine, LMU Munich, Veterinärstr. 13, D-80539 Munich, Germany
| | - Christiane Otzdorff
- Clinic for Small Animal Surgery and Reproduction, Center for Clinical Veterinary Medicine, LMU Munich, Veterinärstr. 13, D-80539 Munich, Germany
| | - Myriam Reichenbach
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, and Center for Innovative Medical Models (CiMM), LMU Munich, Feodor-Lynen-Str. 25, D-81377 Munich, Germany
| | - Horst Dieter Reichenbach
- Bavarian State Research Center for Agriculture - Institute for Animal Breeding, Prof.-Dürrwaechter-Platz 1, D-85586 Grub-Poing, Germany
| | - Alexandra Rieger
- Institute of Veterinary Pathology at the Centre for Clinical Veterinary Medicine, LMU Munich, Veterinärstr. 13, D-80539 Munich, Germany
| | - Birte Rieseberg
- Institute of Veterinary Pathology at the Centre for Clinical Veterinary Medicine, LMU Munich, Veterinärstr. 13, D-80539 Munich, Germany
| | - Marco Rosati
- Institute of Veterinary Pathology at the Centre for Clinical Veterinary Medicine, LMU Munich, Veterinärstr. 13, D-80539 Munich, Germany
| | - Manuel Nicolas Saucedo
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, and Center for Innovative Medical Models (CiMM), LMU Munich, Feodor-Lynen-Str. 25, D-81377 Munich, Germany
| | - Anna Schleicher
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, and Center for Innovative Medical Models (CiMM), LMU Munich, Feodor-Lynen-Str. 25, D-81377 Munich, Germany
| | - Marlon R Schneider
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, and Center for Innovative Medical Models (CiMM), LMU Munich, Feodor-Lynen-Str. 25, D-81377 Munich, Germany
| | - Kilian Simmet
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, and Center for Innovative Medical Models (CiMM), LMU Munich, Feodor-Lynen-Str. 25, D-81377 Munich, Germany
| | - Judith Steinmetz
- Institute of Veterinary Pathology at the Centre for Clinical Veterinary Medicine, LMU Munich, Veterinärstr. 13, D-80539 Munich, Germany
| | - Nicole Übel
- Clinic for Swine at the Centre of Clinical Veterinary Medicine, LMU Munich, Sonnenstr. 16, D-85764 Oberschleißheim, Germany
| | - Patrizia Zehetmaier
- Chair for Animal Physiology, Department of Veterinary Sciences, LMU Munich, Veterinärstr. 13, D-80539 Munich, Germany
| | - Andreas Jung
- Institute of Pathology, LMU Munich, Thalkirchner Str. 36, D-80337 Munich, Germany
| | - Jerzy Adamski
- Genome Analysis Center (GAC), Institute of Experimental Genetics, Helmholtz Zentrum München, Ingolstädter Landstr. 1, D-85764 Neuherberg, Germany; Chair of Experimental Genetics, School of Life Science Weihenstephan, Technische Universität München, Ingolstädter Landstr. 1, D-85764 Neuherberg, Germany
| | - Ünal Coskun
- German Center for Diabetes Research (DZD), Ingolstädter Landstr. 1, D-85764 Neuherberg, Germany; Paul Langerhans Institute Dresden of the Helmholtz Zentrum München at the University Hospital and Faculty of Medicine Carl Gustav Carus of TU Dresden, Fetscherstr. 74, D-01307 Dresden, Germany
| | - Martin Hrabě de Angelis
- German Center for Diabetes Research (DZD), Ingolstädter Landstr. 1, D-85764 Neuherberg, Germany; German Mouse Clinic (GMC), Institute of Experimental Genetics, Helmholtz Zentrum München, Ingolstädter Landstr. 1, D-85764 Neuherberg, Germany; Chair of Experimental Genetics, School of Life Science Weihenstephan, Technische Universität München, Ingolstädter Landstr. 1, D-85764 Neuherberg, Germany
| | | | - Mathias Ritzmann
- Clinic for Swine at the Centre of Clinical Veterinary Medicine, LMU Munich, Sonnenstr. 16, D-85764 Oberschleißheim, Germany
| | - Andrea Meyer-Lindenberg
- Clinic for Small Animal Surgery and Reproduction, Center for Clinical Veterinary Medicine, LMU Munich, Veterinärstr. 13, D-80539 Munich, Germany
| | - Helmut Blum
- Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Feodor-Lynen-Str. 25, D-81377 Munich, Germany
| | - Georg J Arnold
- Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Feodor-Lynen-Str. 25, D-81377 Munich, Germany
| | - Thomas Fröhlich
- Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Feodor-Lynen-Str. 25, D-81377 Munich, Germany
| | - Rüdiger Wanke
- Institute of Veterinary Pathology at the Centre for Clinical Veterinary Medicine, LMU Munich, Veterinärstr. 13, D-80539 Munich, Germany
| | - Eckhard Wolf
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, and Center for Innovative Medical Models (CiMM), LMU Munich, Feodor-Lynen-Str. 25, D-81377 Munich, Germany; German Center for Diabetes Research (DZD), Ingolstädter Landstr. 1, D-85764 Neuherberg, Germany; Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Feodor-Lynen-Str. 25, D-81377 Munich, Germany.
| |
Collapse
|